The aim is to compare the efficacy of daraxonrasib against standard chemotherapy in treating previously treated metastatic pancreatic cancer.
Randomized trial involving patients with previously treated metastatic pancreatic cancer.
Participants were assigned to receive either daraxonrasib or chemotherapy.
Efficacy was assessed based on treatment outcomes.
Daraxonrasib demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy (HR = 0.75, 95% CI 0.60-0.93, p=0.03).
Overall response rate for daraxonrasib was 25%, while chemotherapy had a 15% response rate.
Adverse events were reported in both groups, with daraxonrasib causing fewer severe events (Grade 3 or higher).